NFSG Corp Buys 4,100 Shares of Merck & Co., Inc. $MRK

NFSG Corp lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 31.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,154 shares of the company’s stock after purchasing an additional 4,100 shares during the period. NFSG Corp’s holdings in Merck & Co., Inc. were worth $2,493,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of MRK. Horizons Wealth Management purchased a new position in Merck & Co., Inc. in the 3rd quarter valued at about $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth about $27,000. Graney & King LLC increased its stake in Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $41,000. Finally, Evergreen Advisors LLC purchased a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $145.66 on Friday. The company has a market cap of $359.37 billion, a P/E ratio of 116.53, a P/E/G ratio of 6.81 and a beta of 0.21. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The company’s 50-day moving average price is $145.26 and its 200-day moving average price is $129.12. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is currently 272.00%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck plans to present first-time pivotal Phase 3 data at ESMO 2026 for oncology programs including melanoma and endometrial cancer. The company will also hold an oncology investor event, potentially giving investors greater visibility into growth opportunities beyond Keytruda. What Could Merck Reveal At ESMO 2026 About Its Oncology Pipeline?
• Positive Sentiment: CEO Rob Davis said Merck and Moderna expect manufacturing of their personalized cancer vaccine to become faster over time. Improving production efficiency could support broader commercialization of the vaccine, although manufacturing remains complex. Merck CEO Tells CNBC He Expects Breakthrough Cancer Vaccine Will Become Faster to Make
• Neutral Sentiment: Analysts expect Keytruda sales growth, newer product launches and expanded indications to support third-quarter revenue. However, biosimilar competition is expected to become a more significant risk in 2028–2029, making pipeline execution increasingly important. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Neutral Sentiment: Merck’s dividend yield is about 2.3%, but comparisons with Amgen highlight differing levels of dividend coverage and cash-flow flexibility. The analysis may influence income-focused investors but does not introduce a new company-specific catalyst. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Merck trades at a premium valuation of roughly 5.5 times sales, increasing the market’s expectations for sustained growth. Investors are also monitoring the changing emphasis in management’s strategy and continuing challenges for the Gardasil vaccine business in China. How Has Merck’s Story Changed?

Analysts Set New Price Targets

MRK has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, October 5th. Cantor Fitzgerald lifted their price target on Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Sanford C. Bernstein lifted their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research note on Tuesday, August 4th. Royal Bank Of Canada dropped their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research report on Monday. Finally, Jefferies Financial Group boosted their price target on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 20,784 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the sale, the executive vice president owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.